JTWM
UTHR icon

Jackson Thornton Wealth Management’s United Therapeutics UTHR Stock Holding History

Jackson Thornton Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
374
+14
+4% +$7.88K 0.02% 401
2026
Q1 		$206K Sell
360
-275
-43% -$137K 0.02% 272
2025
Q4 		$319K Buy
+635
New +$296K 0.03% 182

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Jackson Thornton Wealth Management's UTHR Position: Q2 2026 in Review

Jackson Thornton Wealth Management increased its United Therapeutics (UTHR) stake by 3.9% in Q2 2026, buying an estimated $7.88K and bringing the position to 374 shares worth $203K. The position accounts for 0.02% of the portfolio, ranked #401.

Jackson Thornton Wealth Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $319K in Q4 2025. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Jackson Thornton Wealth Management held 374 shares of United Therapeutics worth $203K as of Q2 2026.
  • Jackson Thornton Wealth Management bought 14 United Therapeutics shares in Q2 2026, an estimated $7.88K.
  • United Therapeutics made up 0.02% of Jackson Thornton Wealth Management's portfolio in Q2 2026, its #401 holding.
  • Jackson Thornton Wealth Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Jackson Thornton Wealth Management's United Therapeutics position peaked at $319K in Q4 2025.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.